Department of Psychiatry and Psychotherapy, Saarland University Hospital, Saarland University, Homburg, Germany.
Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, Esch-sur-Alzette, Luxembourg.
Mol Psychiatry. 2020 Mar;25(3):629-639. doi: 10.1038/s41380-018-0091-8. Epub 2018 Jul 9.
Common variants of about 20 genes contributing to AD risk have so far been identified through genome-wide association studies (GWAS). However, there is still a large proportion of heritability that might be explained by rare but functionally important variants. One of the so far identified genes with rare AD causing variants is ADAM10. Using whole-genome sequencing we now identified a single rare nonsynonymous variant (SNV) rs142946965 [p.R215I] in ADAM17 co-segregating with an autosomal-dominant pattern of late-onset AD in one family. Subsequent genotyping and analysis of available whole-exome sequencing data of additional case/control samples from Germany, UK, and USA identified five variant carriers among AD patients only. The mutation inhibits pro-protein cleavage and the formation of the active enzyme, thus leading to loss-of-function of ADAM17 alpha-secretase. Further, we identified a strong negative correlation between ADAM17 and APP gene expression in human brain and present in vitro evidence that ADAM17 negatively controls the expression of APP. As a consequence, p.R215I mutation of ADAM17 leads to elevated Aß formation in vitro. Together our data supports a causative association of the identified ADAM17 variant in the pathogenesis of AD.
迄今为止,通过全基因组关联研究(GWAS)已经确定了大约 20 个与 AD 风险相关的常见基因变体。然而,仍然有很大一部分遗传率可能是由罕见但功能重要的变体来解释的。到目前为止,在 AD 中发现的具有罕见致病变体的基因之一是 ADAM10。使用全基因组测序,我们现在在一个家族中发现了 ADAM17 中与常染色体显性遗传晚发性 AD 共分离的单个罕见非同义变异(SNV)rs142946965 [p.R215I]。随后对来自德国、英国和美国的其他病例/对照样本的可用全外显子组测序数据进行基因分型和分析,仅在 AD 患者中发现了 5 名变异携带者。该突变抑制了前蛋白的切割和活性酶的形成,从而导致 ADAM17 α-分泌酶的功能丧失。此外,我们在人类大脑中发现了 ADAM17 和 APP 基因表达之间的强烈负相关,并提供了体外证据表明 ADAM17 负调控 APP 的表达。因此,ADAM17 的 p.R215I 突变导致体外 Aβ形成增加。我们的数据共同支持在 AD 的发病机制中鉴定出的 ADAM17 变体存在因果关联。